Where Will Nu Holdings Stock Be in 2030?
Despite fast growth, high profitability and an extraordinary runway ahead,…
Buy
60
HLNCF Quote, Financials, Valuation and Earnings
Last price:
$5.1700
Seasonality move
:
13.2%
Day range:
$4.9100 - $5.1900
52-week range:
$3.9000 - $5.4700
Dividend yield:
1.59%
P/E ratio:
24.86x
P/S ratio:
3.20x
P/B ratio:
2.23x
Volume:
4.4K
Avg. volume:
28.1K
1-year change:
19.9%
Market cap:
$45.2B
Revenue:
$14.4B
EPS (TTM):
$0.20
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HLNCF
Haleon PLC
|
$3.7B | -- | 0.78% | -- | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
$7M | -$0.17 | -92.5% | -8.33% | $1.71 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.97 |
|
NCNA
NuCana PLC
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
VRNA
Verona Pharma PLC
|
$53.6M | -$0.03 | -- | -89.84% | $81.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HLNCF
Haleon PLC
|
$5.0000 | -- | $45.2B | 24.86x | $0.03 | 1.59% | 3.20x |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.25 | $1.71 | $64.3M | -- | $0.00 | 0% | 0.36x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$1.20 | $17.97 | $802.3K | -- | $0.00 | 0% | 1.11x |
|
NCNA
NuCana PLC
|
$0.89 | $104.00 | $5.4M | -- | $0.00 | 0% | -- |
|
VRNA
Verona Pharma PLC
|
$58.54 | $81.00 | $5B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HLNCF
Haleon PLC
|
38.17% | 0.121 | 29.54% | 0.75x |
|
ADAP
Adaptimmune Therapeutics PLC
|
80.92% | 4.133 | 36.44% | 2.60x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 1.825 | -- | 1.20x |
|
NCNA
NuCana PLC
|
-- | 0.371 | -- | -- |
|
VRNA
Verona Pharma PLC
|
37.04% | 0.836 | 3.06% | 10.24x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HLNCF
Haleon PLC
|
$2B | $448.1M | 5.64% | 8.91% | 14.46% | $921M |
|
ADAP
Adaptimmune Therapeutics PLC
|
-- | -$57.2M | -93.9% | -140.5% | -2197.67% | -$35.4M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
NCNA
NuCana PLC
|
-- | -$1.6M | -- | -- | -- | -$9.3M |
|
VRNA
Verona Pharma PLC
|
$34.6M | -$17.8M | -60.44% | -88.7% | -41.57% | -$29.4M |
Haleon PLC vs. Competitors
-
Which has Higher Returns HLNCF or ADAP?
Adaptimmune Therapeutics PLC has a net margin of 8.37% compared to Haleon PLC's net margin of -2303.38%. Haleon PLC's return on equity of 8.91% beat Adaptimmune Therapeutics PLC's return on equity of -140.5%.
Company Gross Margin Earnings Per Share Invested Capital HLNCFHaleon PLC55.38% $0.03 $32.9B ADAPAdaptimmune Therapeutics PLC-- -$0.31 $62.1M -
What do Analysts Say About HLNCF or ADAP?
Haleon PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.71 which suggests that it could grow by 582.5%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Haleon PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Haleon PLC.
Company Buy Ratings Hold Ratings Sell Ratings HLNCFHaleon PLC0 0 0 ADAPAdaptimmune Therapeutics PLC2 2 0 -
Is HLNCF or ADAP More Risky?
Haleon PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.845, suggesting its more volatile than the S&P 500 by 184.488%.
-
Which is a Better Dividend Stock HLNCF or ADAP?
Haleon PLC has a quarterly dividend of $0.03 per share corresponding to a yield of 1.59%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haleon PLC pays 39.53% of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend. Haleon PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HLNCF or ADAP?
Haleon PLC quarterly revenues are $3.5B, which are larger than Adaptimmune Therapeutics PLC quarterly revenues of $3.2M. Haleon PLC's net income of $295.8M is higher than Adaptimmune Therapeutics PLC's net income of -$74.2M. Notably, Haleon PLC's price-to-earnings ratio is 24.86x while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon PLC is 3.20x versus 0.36x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLNCFHaleon PLC3.20x 24.86x $3.5B $295.8M ADAPAdaptimmune Therapeutics PLC0.36x -- $3.2M -$74.2M
-
Which has Higher Returns HLNCF or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of 8.37% compared to Haleon PLC's net margin of --. Haleon PLC's return on equity of 8.91% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital HLNCFHaleon PLC55.38% $0.03 $32.9B BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About HLNCF or BDRX?
Haleon PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 1407.64%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Haleon PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Haleon PLC.
Company Buy Ratings Hold Ratings Sell Ratings HLNCFHaleon PLC0 0 0 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is HLNCF or BDRX More Risky?
Haleon PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.705, suggesting its more volatile than the S&P 500 by 70.482%.
-
Which is a Better Dividend Stock HLNCF or BDRX?
Haleon PLC has a quarterly dividend of $0.03 per share corresponding to a yield of 1.59%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haleon PLC pays 39.53% of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend. Haleon PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HLNCF or BDRX?
Haleon PLC quarterly revenues are $3.5B, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Haleon PLC's net income of $295.8M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Haleon PLC's price-to-earnings ratio is 24.86x while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon PLC is 3.20x versus 1.11x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLNCFHaleon PLC3.20x 24.86x $3.5B $295.8M BDRXBiodexa Pharmaceuticals PLC1.11x -- -- --
-
Which has Higher Returns HLNCF or NCNA?
NuCana PLC has a net margin of 8.37% compared to Haleon PLC's net margin of --. Haleon PLC's return on equity of 8.91% beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HLNCFHaleon PLC55.38% $0.03 $32.9B NCNANuCana PLC-- -$0.32 -- -
What do Analysts Say About HLNCF or NCNA?
Haleon PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 11585.39%. Given that NuCana PLC has higher upside potential than Haleon PLC, analysts believe NuCana PLC is more attractive than Haleon PLC.
Company Buy Ratings Hold Ratings Sell Ratings HLNCFHaleon PLC0 0 0 NCNANuCana PLC0 1 0 -
Is HLNCF or NCNA More Risky?
Haleon PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NuCana PLC has a beta of 1.464, suggesting its more volatile than the S&P 500 by 46.355%.
-
Which is a Better Dividend Stock HLNCF or NCNA?
Haleon PLC has a quarterly dividend of $0.03 per share corresponding to a yield of 1.59%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haleon PLC pays 39.53% of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend. Haleon PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HLNCF or NCNA?
Haleon PLC quarterly revenues are $3.5B, which are larger than NuCana PLC quarterly revenues of --. Haleon PLC's net income of $295.8M is higher than NuCana PLC's net income of -$836.1K. Notably, Haleon PLC's price-to-earnings ratio is 24.86x while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon PLC is 3.20x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLNCFHaleon PLC3.20x 24.86x $3.5B $295.8M NCNANuCana PLC-- -- -- -$836.1K
-
Which has Higher Returns HLNCF or VRNA?
Verona Pharma PLC has a net margin of 8.37% compared to Haleon PLC's net margin of -92.29%. Haleon PLC's return on equity of 8.91% beat Verona Pharma PLC's return on equity of -88.7%.
Company Gross Margin Earnings Per Share Invested Capital HLNCFHaleon PLC55.38% $0.03 $32.9B VRNAVerona Pharma PLC94.44% -$0.40 $324.9M -
What do Analysts Say About HLNCF or VRNA?
Haleon PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand Verona Pharma PLC has an analysts' consensus of $81.00 which suggests that it could grow by 38.37%. Given that Verona Pharma PLC has higher upside potential than Haleon PLC, analysts believe Verona Pharma PLC is more attractive than Haleon PLC.
Company Buy Ratings Hold Ratings Sell Ratings HLNCFHaleon PLC0 0 0 VRNAVerona Pharma PLC5 0 0 -
Is HLNCF or VRNA More Risky?
Haleon PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.165, suggesting its less volatile than the S&P 500 by 83.527%.
-
Which is a Better Dividend Stock HLNCF or VRNA?
Haleon PLC has a quarterly dividend of $0.03 per share corresponding to a yield of 1.59%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haleon PLC pays 39.53% of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend. Haleon PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HLNCF or VRNA?
Haleon PLC quarterly revenues are $3.5B, which are larger than Verona Pharma PLC quarterly revenues of $36.7M. Haleon PLC's net income of $295.8M is higher than Verona Pharma PLC's net income of -$33.8M. Notably, Haleon PLC's price-to-earnings ratio is 24.86x while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon PLC is 3.20x versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLNCFHaleon PLC3.20x 24.86x $3.5B $295.8M VRNAVerona Pharma PLC-- -- $36.7M -$33.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is it Too Late to Buy United Airlines Stock?
United Airlines (NASDAQ:UAL) has thoroughly outpaced the broader stock market…
3 Smartest Dividend Stocks to Buy Now
When the market entered a correction in February and March,…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
GATE alert for Apr 2
Marblegate Acquisition [GATE] is up 86.64% over the past day.
Buy
52
NUTX alert for Apr 2
Nutex Health [NUTX] is up 5.41% over the past day.
Buy
75
CORT alert for Apr 2
Corcept Therapeutics [CORT] is down 8.84% over the past day.
